Search results

olaparib (Lynparza)

In combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with metastatic castration-resistant prostate cancer in whom chemotherapy is not clinically indicated.

niraparib / abiraterone (Akeega)

With prednisone or prednisolone for the treatment of adult patients with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 gene mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.

cabazitaxel (Jevtana)

Cabazitaxel in combination with prednisone or prednisolone is indicated for the treatment of adult patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.

abiraterone (Zytiga)

With prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

abiraterone acetate (Zytiga)

with prednisolone for the treatment of adult men with newly diagnosed high-risk metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT)

abiraterone (Zytiga)

abiraterone acetate is indicated with prednisone or prednisolone for the treatment of metastatic castration resistant prostate cancer (mCRPC) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

rituximab subcutaneous (Mabthera)

For non-Hodgkin' s lymphoma (NHL) in adults: - previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy; - maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy; - treatment of patients with CD20 positive diffuse large B cell - non-Hodgkin's lymphoma in combination with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy.

ibrutinib (Imbruvica)

In combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) alternating with rituximab, dexamethasone, high-dose cytarabine and cisplatin (R-DHAP) or rituximab, dexamethasone, high-dose cytarabine and oxaliplatin [R-DHAOx]) without ibrutinib, followed by ibrutinib monotherapy is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who would be eligible for autologous stem cell transplantation (ASCT).

lenalidomide (Revlimid)

treatment of adult patients with previously untreated multiple myeloma who are not eligible for transplant.

Rituximab (MabThera®)

Follicular lymphoma in combination with CVP chemotherapy

budesonide 3mg gastro-resistant capsules (Budenofalk)

Autoimmune hepatitis.

budesonide (Cortiment)

in adults for induction of remission in patients with mild to moderate active ulcerative colitis (UC) where aminosalicylate (5-ASA) treatment is not sufficient.

rituximab (MabThera)

for the treatment of previously untreated patients with stage III-IV follicular lymphoma in combination with chemotherapy

May 2015 decisions news release

The Scottish Medicines Consortium (SMC) has today published advice accepting seven new medicines for use in NHSScotland.